Navigation Links
Lotus Pharmaceuticals Terminates SEDA
Date:7/22/2010

BEIJING, July 22 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), announced today that it has entered into a termination agreement with Yorkville Global Master SPV Ltd. ("Yorkville") whereby the parties agreed to mutually terminate the Standby Equity Distribution Agreement, dated March 3, 2010, between the company and Yorkville (the "SEDA") with no further obligations.

CEO, Dr. Zhongyi Liu, commented, "We appreciate the capital commitment from Yorkville, but we won't utilize the SEDA. The reason is that currently we have sufficient working capital and growth capital to carry out the construction and outfitting of our new building complex in Beijing, which is expected to open in 2010. We will consider alternative funding options and structures only when our stock valuation improves, in order to protect against stock dilution."

About Lotus Pharmaceuticals, Inc. (http://www.lotuspharma.com )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of drugs and a licensed national seller of pharmaceutical items in the PRC. Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular disease
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
2. Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform
3. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
4. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
5. Lotus Pharmaceuticals to Exhibit at the 63rd PHARMCHINA
6. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
7. Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores
8. Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA
9. Lotus Pharmaceuticals, Inc. Reports Third-Quarter 2009 Results
10. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
11. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very pleased ... as its new Chief Executive Officer.  Mark was promoted ... he has overseen the company,s four facilities in ... Rica.  Mr. King joined Tegra Medical in 2012 with 20+ ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:4/18/2014)... news release is available in French . ... could revolutionize surgical practice and regenerative medicine. A team ... et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from ... Paris 13), has just demonstrated that the principle of ... in vivo to repair soft-tissue organs and tissues. This ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2
... Prompts Extension of Promotion -, DENVER, July ... of functional foods, beverages and nutritional,supplements, announced that ... of the $1 million sales goal for the ... opportunity to earn,significant bonuses in July., John ...
... hardest hit states by this legislation, WASHINGTON, July ... significant funding cuts under legislation being,considered in Congress, according ... As Congress considers ways to halt the impending cut ... Medicare Advantage program to,pay for the fix. Legislation currently ...
... July 2 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... the minimally invasive treatment of venous reflux disease, ... in the United States,District Court, Northern District of ... (Dornier) and NewStar Lasers,Inc. d/b/a CoolTouch, Inc. (CoolTouch)., ...
... ushers in The Art of Condoms (FDA-approved), as the ... latest hi-tech advancement in safe-sex., ... of designer-condoms. Remarkably shaped condoms,including the look-alike Dolphin Condom(TM) and ... designers could only dream,of making before. The Dolphin(TM) has all ...
... for environment, MELROSE PARK, Ill., July 2 ... that it has surpassed the,sale of 1 million green ... "We are seeing more and more people buying ... Jewel-Osco. "This is,likely due to the heightened awareness about ...
... disease can save some vision, experts say , , WEDNESDAY, ... to end in blindness, two new studies suggest. , ... for glaucoma has better outcomes than using glaucoma drainage ... end-stage glaucoma can be successfully treated. Both studies were ...
Cached Medicine News:Health News:XELR8 Holdings Announces Continuation of 'XELR8 To A Million' Promotion 2Health News:Proposed Congressional Legislation Would Cut $784 Million From the Medicare Advantage Program in New York 2Health News:VNUS Medical Technologies, Inc. Files Patent Infringement Lawsuits Against Biolitec, Dornier and CoolTouch 2Health News:The New Condom That Breaks - - - the Mold. 2Health News:Jewel-Osco: 1 Million Reusable Shopping Bags Sold 2Health News:Glaucoma Treatment Can Prevent Blindness 2Health News:Glaucoma Treatment Can Prevent Blindness 3
15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle....
15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle. Designated most popular model or size....
8 mm curved blade. Cutting edge on inside of curve. Flat handle....
For use with N4096 R, N4097 R and N4098 R. 18 mm wide x 167 mm long. Ten per package. Designated most popular model or size....
Medicine Products: